Factors influencing bone loss in rheumatoid arthritis: A longitudinal study
|
|
- Jessica Sanders
- 6 years ago
- Views:
Transcription
1 Factors influencing bone loss in rheumatoid arthritis: A longitudinal study B. Cortet 1, M.-H. Guyot 1, E. Solau 1, P. Pigny 2, F. Dumoulin 1, R.-M. Flipo 1, X. Marchandise 3, B. Delcambre 1 1 Department of Rheumatology, CHRU Lille, Hôpital R. Salengro; 2 Department of Biochemistry, CHRU Lille, Clinique Marc Linquette; 3 Department of Nuclear Medicine, CHRU Lille, Hôpital R. Salengro, Lille, France. Abstract Objectives To assess the occurrence of bone loss in rheumatoid arthritis (RA) and to determine the factors influencing bone loss (particularly the usefulness of bone turnover markers) over an 18-month period. Methods A total of 51 patients were studied, 6 men and 45 females (of whom 35 were menopausal). Their mean age was 56 ± 10 years and the mean RA duration was 12 ± 10 years. Twenty-eight (55%) were receiving corticosteroids (10 mg/day for a mean duration of 6 ± 5 years). Several clinical and biological parameters reflecting disease activity or severity were recorded both at the 0 and 18-month investigations. Bone turnover was assessed at baseline by measuring the serum levels of 4 biological markers. Three of them reflected bone formation, i.e., procollagen type I C-terminal propepeptide (PICP), procollagen type I N-terminal propeptide (PINP) and osteocalcin (OC). The fourth, procollagen type I-C terminal telopeptide (ICTP), reflected bone resorption. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry both at the lumbar spine (LS) and femoral neck (FN) at baseline and 18 months later. Results Bone loss occurred both at the LS: 2.1%, [95% CI: 0.8% - 3.4%, P < 0.005] and femoral neck: 3.1%, [95% CI: 1.1% - 5.1%, P < 0.005]. Bone loss was markedly increased for postmenopausal women at the FN: 5.3% [95% CI: 2.9% - 7.6%, P < 0.005]. Bone loss was not statistically significantly different between users and non-users of steroids. Bone loss at the LS was significantly correlated with both osteocalcin (r = 0.51, P < 0.01) and ICTP levels (r = 0.32, P < 0.05). FN bone loss was correlated with the osteocalcin level only (r = 0.34, P < 0.05). Fast losers (bone loss at the LS above the median) had higher OC (P < 0.01) and ESR (P < 0.05) levels at baseline as compared with slow losers (bone loss at the LS below the median). Conclusion Bone loss occurs in RA particularly at the FN and seems to be influenced by increased bone turnover and high levels of inflammation. Key words Rheumatoid arthritis, bone loss, markers of bone turnover, dual-energy X-ray absorptiometry. Clinical and Experimental Rheumatology 2000; 18:
2 Bone loss in RA / B. Cortet et al. Bernard Cortet, MD, Hospital Practitioner; Marie-Hélène Guyot, MD, Head Clinical Assistant; Elisabeth Solau, MD, Head Clinical Assistant; Pascal Pigny, MD, PhD, University Conference Master; Florence Dumoulin, Registrar; René-Marc Flipo, MD, Professor of Rheumatology; Xavier Marchandise, MD, PhD, Professor of Nuclear Medicine; Bernard Delcambre, MD, Professor of Rheumatology. Please address correspondence and reprint requests to: Bernard Cortet, Department of Rheumatology, CHRU Lille, Hôpital R. Salengro, 2 Avenue Oscar Lambret, Lille Cedex, France. address: bcortet@chru-lille.fr Received on February 9, 2000; accepted in revised form on August 21, Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Introduction Although generalized osteoporosis is a well-known extra-articular manifestation of rheumatoid arthritis (1-4) leading to increased fracture risk, few studies have assessed the occurrence of bone loss (longitudinal studies) in rheumatoid arthritis (5-10). Moreover, data available on this issue are conflicting, perhaps due to variations in bone mass measurement techniques, study population characteristics, and follow up duration. Thus, some authors found that patients with rheumatoid arthritis (RA) lost bone (7, 9-11), while others did not find any bone loss in RA or only in patients for whom the disease duration was shorter than 6 months (5, 6, 8, 12). Furthermore, although corticosteroids are well known to cause bone loss, there are some discrepancies regarding this issue in RA patients (8, 9, 10, 13). In fact, in RA corticosteroids are usually used at low doses which should theoretically be safe for bone tissue. Is is also important to note that corticosteroids improve disease activity which is associated with accelerated bone loss in RA (7, 11). The mechanisms leading to bone loss in RA are not yet well documented, but are hypothesized to involve an increase of bone resorption possibly due to an increase in pro-inflammatory cytokines which play a role in the pathogenesis of the disease, a decrease in bone formation or both (13-22). The most recent data suggest however that osteoclastic activation is the principal mechanism leading to osteoporosis in RA (4, 11). In three recent cross-sectional studies (3, 4, 23) we showed that patients with RA had decreased values of bone mineral density (BMD) at the femoral neck and elevated levels of bone turnover markers, namely procollagen type I C-terminal propeptide (PICP), procollagen type I N-terminal propeptide (PINP) which reflects bone formation, and procollagen type I C-terminal telopeptide (ICTP) which reflects bone resorption. The main purpose of the present study was to determine whether or not bone loss occurs in RA over an 18-month period. The second objective was to assess the factors influencing bone loss in RA and, particularly, the role of bone turnover markers in predicting bone loss. Patients and methods Patients The patients who participated in this longitudinal study fulfilled the American College of Rheumatology criteria for RA (24). They have been partly described in three previous cross-sectional studies (3, 4, 23). Eighty-five unselected, consecutive Caucasian patients were enrolled in this study. After the exclusion of patients for whom bone markers data were not collected and patients who were receiving drugs which could affect bone mass or bone metabolism (i.e., calcium, vitamin D, bisphosphonates, hormone replacement therapy or fluoride salts), 51 patients were eligible for the study. Several patients were receiving corticosteroids and/or methotrexate and/or cyclosporin. None of the patients received intramuscular injections of corticosteroid during the follow up, while 5 patients received intra-articular injections during the follow up. For the latter patients these injections were taken into account when calculating the cumulative dose of corticosteroids. The study was conducted from January 1995 to December It was approved by our local ethics committee and all patients gave their informed consent to participate. Bone densitometry BMD was measured by dual-energy X- ray absorptiometry (DEXA, Sophos L- XRA, Buc/Yvette, France) at the lumbar spine (L2-L4) and the non-dominant femoral neck at the 0 and 18-month clinical examinations. The in vivo reproducibility of this measurement, expressed as the coefficient of variation, was 1% for the lumbar spine and 1.6% for the femoral neck. The individual values for the BMD were also expressed as a fraction of the SD of the mean of the normal value for the patients s sex and decade of age (Z-score), but also as a fraction of the SD of the normal values for young adults of the same sex (T-score). Clinical data collection The following parameters reflecting activity or severity were determined twice (at baseline and at the 18-month evaluation): duration of morning stiffness, num- 684
3 Hypothalamus-pituitary-adrenocortical and -gonadal axis in RA / M. Cutolo Bone loss in RA / EDITORIAL B. Cortet et al. ber of painful and swollen joints, Ritchie articular index (25), Lee s Index (26), and the health assessment questionnaire (HAQ) score (27). In steroid-treated patients, the duration of treatment, the mean daily dose and the cumulative dose were also recorded (prednisone-equivalent). Finally, the number of patients who were taking second-line drugs and, in particular, methotrexate was also recorded. The erythrocyte sedimentation rate (ESR, by the Westergren method) and C-reactive protein level (CRP, by laser immunonephelometry) were measured after an overnight fast at baseline and at the 18- month evaluation. Multiple regression models (stepwise multiple regression analysis) were constructed to identify independent factors influencing bone loss. Several models were constructed based on the results of simple regression analysis and the best model for explaining bone loss either at the lumbar spine or femoral neck was chosen. Two subgroups were also identified according to BMD changes: (i) fast losers whose bone loss was above the median [both for the lumbar spine (1.9%) and the femoral neck (3.1%)]; and (ii) slow losers whose bone loss was below the median (both for the lumbar spine and femoral neck). P values < 0.05 were considered statistically significant. Results RA findings The main characteristics of the 51 patients are summarized in Table I. There were 45 women (91%) and 6 men. Thirty-five of the women were menopausal (77%). The mean age of the patients was 56 ± 10 years and the mean disease duration was 12 ± 10 years. Forty-one patients (80%) had positive tests for rheumatoid factors and 28 (55%) were receiving corticosteroid therapy with a mean treatment duration of 6 ± 5 years and a mean daily dose of 10 ± 4 mg/day. Patients who were receiving corticosteroids did not differ at baseline from patients who were on corticosteroids (Table II). Bone turnover markers The following serum assays were undertaken at baseline only: PICP, PINP and osteocalcin (OC) which reflect bone formation, and ICTP which reflects bone resorption. Blood samples were collected between 7:30 am and 9:00 am after an overnight fast. Serum samples were stored at -80 until assayed. Radioimmunologic assays were used to measure serum PICP, PINP, ICTP (Orion Diagnostica, Espoo, Finland) and osteocalcin (Cis-Bio International, Gif/Yvette, France). The within run and run-to-run coefficients of variation were 2.8% and 5.1%, respectively, for the PICP assay. The corresponding figures were 8.75% and 5.1% for the PINP assay, 4.8% and 5.7% for the ICTP assay and 3.7% and 6.6% for the osteocalcin assay. Statistical analysis All analyses were performed using the Statview program (version 5, SAS Institute, Cary, NC, USA). Group data are expressed as the mean ± standard deviation (SD) or mean ± 95% confidence interval (CI). The incremental percentage change in BMD was calculated for each patient at both the lumbar spine and femoral neck. Statistical comparisons were made using Student s-t-test for paired data or Wilcoxon s test as appropriate. The comparisons of BMD changes according to sex or menopausal status were performed using analysis of variance or the Kruskal-Wallis test. Simple linear regression was used to determine the coefficients of correlation. Table I. Main features of the 51 rheumatoid arthritis patients at baseline. Age (years) 56 ±10 Weight (kg) 69 ± 15 Height (cm) 163 ± 9 Number of women 45 (88%) Number of postmenopausal women 35 (80%) Rheumatoid arthritis duration (years) 12 ± 10 Positive rheumatoid factor 41 (80%) Steroid therapy 28 (55%) Duration of steroid therapy (years) 6 ± 5 Cumulative steroid dose (grams) 20 ± 20 Mean daily dose of steroids (mg/day) 10 ± 4 Morning stiffness duration (mn) 82 ± 106 Number of painful joints 11 ± 10 Number of swollen joints 7 ± 5 Lee s index 13 ± 10 Ritchie articular index 14 ± 9 Health assessment questionnaire score 1.6 ± 0.7 Table II. Comparison at baseline of patients according to their corticosteroid status. Cortico+: patients with corticosteroids, Cortico-: patients without corticosteroids. There was no significant difference between the 2 subgroups (cortico+ versus cortico-). Cortico+ Cortico- Age (years) 57 ± 9 55 ± 13 Weight (kg) 66 ± ± 16 Height (cm) 165 ± ± 8 Number of women 24/28 (86%) 21/23 (91%) Number of postmenopausal women 21/35 (60%) 7/10 (70%) RA duration (years) 13 ± ± 7 Morning stiffness duration (mn) 121 ± ± 63 Number of painful joints 13 ± 12 10± 10 Number of swollen joints 7 ± 5 5 ± 5 Lee s index 15 ± ± 10 Ritchie articular index 14 ± 9 14 ± 9 Health assessment questionnaire score 1.7 ± ± 0.7 Erythrocyte sedimentation rate (mm/h) 50 ± ± 32 C-reactive protein level (mg/l) 42 ± ±
4 Bone loss in RA / B. Cortet et al. Table III. Bone mineral density (BMD) with Z- and T-scores and markers of bone turnover in 51 patients with rheumatoid arthritis (baseline and 18 month evaluations). 0 months 18 months LS BMD (g/cm 2 ) 0.94 ± ± 0.13* Lumbar spine Z-score ± ± 0.64* Lumbar spine T-score ± ± 0.95 FN BMD (g/cm 2 ) 0.73 ± ± 0.11** Femoral neck Z-score ± ± 0.70* Femoral neck T-score ± ± 0.93 PICP (ng/ml) ± NP PINP (ng/ml) ± NP ICTP (ng/ml) 5.90 ± 2.61 NP Osteocalcin (ng/ml) 5.8 ± 2.62 NP LS: lumbar spine; FN: femoral neck; PICP: procollagen type I C-terminal propeptide; PINP: procollagen type I N-terminal propeptide; ICTP: procollagen type I C-terminal telopeptide. *P < 0.01, **P < (versus baseline). NP: not performed. Fig. 1. Bone mineral density (BMD) changes at the lumbar spine and femoral neck in 51 patients with rheumatoid arthritis (error bars = SEM). Fig. 2. Bone mineral density (BMD) changes at the femoral neck in 51 patients with rheumatoid arthtritis according to sex and menopausal status (error bars = SEM) Forty-eight patients (94%) were receiving a slow-acting anti-rheumatic drug and among them 20 (42%) were taking methotrexate. The others were receiving intra-muscular gold (n = 10, 20%), sulphasalazine (n = 5, 10%), hydroxychloroquine (n = 4, 8%), cyclosporin A (n = 4, 8%), tiopronin (sulphydryl compound, n = 3, 6%) and finally azathioprin (n = 2, 6%). Bone mineral density Table III shows the BMD values, Z- scores and T-scores at baseline and at the 18-month investigation. BMD changes expressed as a percentage are also represented in Figure 1. Significant bone loss occurred both at the lumbar spine: 2.1%, [95% CI: 0.8% - 3.4%, P < 0.005] and femoral neck: 3.1% [95% CI: 1.1% - 5.1%, P < 0.005]. Bone loss was not statistically significantly different in steroid-treated patients as compared with nonsteroid-treated patients both at the lumbar spine and femoral neck: 2.1% ± 4 versus 2.1% ± 5 (P = 0.9) and 2.7% ± 6 versus 4.1% ± 8 (P = 0.5) respectively. Bone loss at the lumbar spine was: 1.2% ± 3.4 for males, 3.4% ± 4.3 for premenopausal women and 1.8% ± 4.9 for postmenopausal women. Bone loss at the lumbar spine was statistically significant for premenopausal women only [95% CI: 0.7% %, P < 0.05]. Bone loss at the lumbar spine (expressed as percentage) was not statistically significantly different, however, in the 3 subgroups previously defined (men, and premenopausal and postmenopausal women). Bone loss at the femoral neck was increased in postmenopausal women as compared with premenopausal women: 5.3% ± 6 versus 0.7% ± 6.6 (P < 0.05). In men a non-significant bone gain was observed (+2.5% ± 7). BMD changes at the femoral neck were significantly different between postmenopausal women and men (P < 0.01). Bone loss at the femoral neck was statistically significant for postmenopausal only [95% CI: 2.9% - 7.6%, P < ]. Bone loss was not different between those patients taking and those not taking methotrexate, both at the lumbar spine and at the femoral neck (P =
5 Hypothalamus-pituitary-adrenocortical and -gonadal axis in RA / M. Cutolo and P = 0.9 respectively). Fast losers at the lumbar spine were characterized at baseline by elevated levels of both osteocalcin and ESR as compared with slow losers: 62 mm ± 34 versus 42 mm ± 23 (P < 0.05) and 6.9 ng/ml ± 2.3 versus 4.7 ng/ml ± 2.6 (P < 0.01) respectively. Determinants of bone loss Simple regression analysis. The changes in BMD both at the lumbar spine and femoral neck were not correlated with either the clinical and biological data at the first visit (disease duration, morning stiffness duration, number of painful and swollen joints, Ritchie articular index, Lee s Index, HAQ score, ESR and CRP levels) or with the changes in clinical and biological data beween the 0 and the 18- month evaluations (Table IV). Moderate correlations were found between bone loss and the levels of some bone turnover markers. Bone loss at the lumbar spine was significantly correlated with both osteocalcin (r = 0.51, P < 0.005) and ICTP levels (r = 0.32, P < 0.05). Bone loss at the femoral neck was correlated with osteocalcin levels only (r = 0.34, P < 0.05). No other correlations were found between the level of bone turnover markers at baseline and the changes in BMD both at the lumbar spine and femoral neck (Table IV). Stepwise multiple regression analysis. Several models were constructed to explain both the lumbar spine and femoral neck bone loss by stepwise multiple regression analysis. At the lumbar spine the only significant predictor was the osteocalcin level which, however, explained only 22% of the variation in BMD changes (adjusted R 2 ). None of the models constructed to explain BMD changes at the femoral neck achieved an adjusted R 2 greater than 0.15, showing the weak predictive effect for this population. Discussion Although generalized osteoporosis is a well-known extra-articular manifestation of RA (1-4), few studies have focused on the occurrence of bone loss in RA (5-12). Moreover the most recent studies addressing this issue have yielded conflicting results (6, 7, 10-12). Thus Gough et al. in 2 recent studies (7, 11) found that patients with early RA had faster bone loss both at the lumbar spine and at the hip than that observed in a control group. Table IV. Correlation between the first visit clinical and biological data (including markers of bone turnover) and bone loss both at the lumbar spine and femoral neck. Lumbar spine bone loss Femoral neck bone loss Age Weight Height RA duration Lee s index Ritchie articular index HAQ score Morning stiffness duration ESR CRP level Steroid duration Cumulative dose of steroids PICP level PINP level Osteocalcin level 0.51** 0.34* ICTP level 0.32* 0.19 HAQ: health assessment questionnaire; ESR: erythrocyte sedimentation rate; CRP: c-reactive protein, PICP: procollagen type I C-terminal propeptide; PINP: procollagen type I N-terminal propeptide; ICTP: procollagen type I C-terminal telopeptide.**p < 0.005, *P < Bone loss in RA / EDITORIAL B. Cortet et al. Moreover, bone loss was slightly greater in the first year as compared with the second year of follow up. Conversely Shenstone et al. (6), who studied 67 patients with RA of less than 5 years duration and 72 controls over a 12-month period, found that bone loss was low (about 1%) and comparable in patients and controls. However, they also found that bone loss at the femoral neck was faster in those patients who had experienced onset of their disease less than 6 months earlier, as compared with the controls and the patients who had more long-standing disease. Finally Aman et al. (12), who studied 52 patients with early RA (i.e., of less than 5 years duration), over a 24 month-period did not find any bone loss. The reasons for these discrepancies are unclear since these 4 recent studies used the same method, DEXA, to measure BMD and the study populations were very comparable (early RA). It is, however, possible that the patients who were early referrals by primary care physicians to the district rheumatism hospital and who therefore represented a community-based population had less severe disease compared with patients who were attending a secondary or tertiary care hospital. Our study suggests that bone loss occurs even in patients with late RA. Although bone loss was statistically significant both at the lumbar spine and at the femoral neck, it was faster at the femoral neck as compared with the lumbar spine: 3.1% versus 2.1%. Bone loss was also significant both at the lumbar spine and at the femoral neck after adjustment for age, i.e. when taking into account the mean Z-score changes. These findings are in agreement with the recent study by Gough et al. (11), who found that the mean percentage change in BMD in patients with RA was -1.8% and -2.8% over a 12- month period at the lumbar spine and the femoral neck, respectively. They also found that bone loss occurred during the second year of follow up: 1.4% (lumbar spine) and 2.4% (femoral neck) respectively. Finally they showed that patients with RA lost bone significantly faster than controls both at the 12-month and 24-month investigations. Nevertheless, we cannot strictly compare our findings with those of Gough et al. since ours was 687
6 Bone loss in RA / B. Cortet et al. an open study (i.e., there was no control group). Our study suggests that bone loss was the same in steroid and non-steroid treated patients: 2.1% ± 4 versus 2.1% ± 5 at the lumbar spine and 2.7% ± 6 versus 4.1% ± 8 at the femoral neck, respectively. Although steroids are known to cause bone loss, they also improve disease activity which is associated with accelerated bone loss in patients with RA (7, 11). Moreover, the low doses usually used in RA ( 10 mg/day of prednisoneequivalent) might be safe for bone tissue. Our findings are in agreement with the metaanalysis of Verhoeven and Boers (13) who found that patients with RA and treated by steroids (mean daily of prednisone: 7 mg) did not lose bone. In fact, the authors found that the mean annual change in BMD was 0% [95% CI: -0.6% to +0.7%] at the lumbar spine. They also found significant bone loss at the lumbar spine (mean annual change) in non- RA patients taking a mean dose of 20 mg prednisone/day: -4.7% [95% CI: -5.2% to -4.3%], suggesting that the steroid dose used may have a major effect on bone loss. Moreover, as indicated in Table II, the 2 subgroups of patients defined according to corticosteroid status did not differ at baseline and this finding emphasizes our conclusion that bone loss is not higher in patients who are treated with corticosteroids as compared with those who are not. On the other hand, we recently showed (28) that patients with RA for whom steroids were given for less than 3 months lost bone significantly at the lumbar spine over a 12-month period despite the fact that they also received 500 mg of supplemental calcium per day. In fact, the mean bone loss per year (± SEM) at the lumbar spine was 2.70% ± Nevertheless, in that study the parameters reflecting the severity and activity of RA were not measured and we cannot exclude the possibility that they had a major influence on bone loss (perhaps greater than the influence of steroid therapy). Although methotrexate osteopathy is a well-known entity (29, 30), the present study suggests that methotrexate does not seem to influence bone loss in patients with RA. This finding is in agreement with one recent study on this issue (31). Our study suggests that bone loss occurs at the femoral neck in postmenopausal women: 5.3% [95% CI: 2.9% - 7.6%, P < ]. Our findings are in agreement with the study of Eggelmeijer et al. (32) who found after 36 months of follow up that postmenopausal women with RA lost bone at the femoral neck. In fact, they found that the mean change in the femoral neck BMD for postmenopausal women was -8.1%. Gough et al. (7) also found that bone loss was greater for postmenopausal women as compared with premenopausal women at the femoral neck over a 1-year period (2.6% versus 1.6%). We found that bone loss was statistically significant in premenopausal women solely at the lumbar spine: 3.4% [95% CI: 0.7% %, P < 0.05]. We do not have any satisfying explanation for this finding. Gough et al. (19) also found in a small sample of premenopausal women with RA that bone loss over 1 year was increased at the lumbar spine as compared with postmenopausal women (1.8% versus 0.1%). Finally, it is also important to note that the number of premenopausal women in the present study was low (n = 10, against 35 postmenopausal women) and therefore the above finding must be interpreted cautiously. None of the first visit clinical and biological data (disease duration, morning stiffness duration, number of painful and swollen joints, Ritchie articular index, Lee s Index, HAQ score, ESR and CRP levels) was correlated with the changes in BMD either at the lumbar spine or the femoral neck. In contrast Gough et al. (7, 11) found that the initial HAQ score was moderately correlated with BMD changes over one year both at the lumbar spine (P < 0.05) and femoral neck (P < 0.01). Furthermore, in a previous cross-sectional study we showed a negative correlation between the HAQ score and BMD (r = for both the lumbar spine and femoral neck). Data (not shown) were very similar for the present study: r = (lumbar spine) and r = (femoral neck), respectively. Hence disability seems to be a relevant factor for explaining osteoporosis in patients with RA. However, in the present study the duration of the follow up was probably too short to detect an influence of the HAQ score on bone loss. Although the ESR at baseline was not correlated with the change in BMD, we found that ESR might be a determinant of bone loss. In fact, fast bone losers had increased ESR levels at baseline compared with slow losers. This finding is in agreement with the two studies by Gough et al. (7, 11) who found that patients whose mean CRP over 1 year was > 20 mg/l showed significantly greater bone loss compared to patients with inactive disease. In the same manner Eggelmeijer et al. (32) found that losses in the femoral neck were more marked in patients with active disease (ESR at baseline 20 mm/hr). Our study supports the hypothesis that increased bone turnover is a determinant of bone loss in patients with RA. In fact, bone loss at the lumbar spine was significantly correlated with both osteocalcin (r = 0.51, P < 0.01) and ICTP levels (r = 0.32, P < 0.05). Bone loss at the femoral neck was correlated with osteocalcin levels only (r = 0.34, P < 0.05). There was no significant correlation, however, with the other markers of bone formation (i.e., PINP and PICP). Although osteocalcin is a well-known marker of bone formation, it has been clearly demonstrated that osteocalcin levels are increased when bone turnover (and not only bone formation) is increased. For instance, Garnero et al. (33) in the OFELY study showed that osteocalcin levels increased by approximately 50% in postmenopausal women as compared with premenopausal women. It is clear, however, that theoretically the correlation between bone loss and the level of markers of bone turnover should be stronger for markers of bone resorption than for markers of bone formation. This apparent discrepancy could be due to the lack of sensitivity of ICTP as compared with other markers of bone resorption and particularly the urinary type I collagen C-telopepetide breakdown products (CTX). It is also important to note that data are limited and conflicting regarding the relationship between the level of bone turnover as assessed by the measurement of markers of bone turnover and bone loss 688
7 Hypothalamus-pituitary-adrenocortical and -gonadal axis in RA / M. Cutolo Bone loss in RA / EDITORIAL B. Cortet et al. in RA patients (11, 12, 19). More generally, the usefulness of markers of bone turnover for predicting bone loss in postmenopausal women is still debated and a recent paper by Marcus et al. (34) showed that the levels of several markers of bone turnover did not correlate with bone loss in postmenopausal women. Furthermore, we found that fast losers of bone had, at baseline, higher levels of oseocalcin as compared with slow losers. In a previous study (4) we showed that both osteocalcin and ICTP levels were correlated with BMD, particularly at the femoral neck (r = and r = -0.29, respectively). In the present study (data not shown), ICTP levels were also correlated with baseline BMD both at the lumbar spine (r = -0.5) and femoral neck (r = -0.39). Conversely Gough et al. (11) found no correlation at baseline between pyridinoline or deoxypyridinoline excretion and BMD. However, they studied patients with early RA (less than 2 years duration) whereas we studied patients with late RA (mean duration 12 ± 10 years). They also showed that both pyridinoline and deoxypyridinoline excretion correlated closely with BMD changes. Unfortunately, pyridinoline and deoxypyridinoline excretion were not assessed in the present study. However it is important to note that these 2 bone turnover markers have a poor precision (intra-assay variation 15% for deoxypyridinoline) compared with the markers measured in the present study (intra-assay variation 5%). Furthermore, it is well known that the timing of urine sampling can significantly alter excretion rates. Finally the gold-standard method, i.e. high performance liquid chromatography for measuring pyridinoline and deoxypyridinoline, is neither simple nor readily available. In conclusion, this study suggests that bone loss occurs in patients with RA, particularly at the femoral neck. Bone loss is associated with increased bone turnover as assessed by high osteocalcin and ICTP levels, but also with persistent inflammation as indirectly measured by the ESR. References 1. CORTET B, FLIPO RM, DUQUESNOY B, DELCAMBRE B: Bone tissue in rheumatoid arthritis (1). Bone mineral density and fracture risk. Rev Rhum [Engl. Ed.] 1995; 62: CORTET B, FLIPO RM, DUQUESNOY B, DELCAMBRE B: Bone tissue in rheumatoid arthritis (2). Pathophysiologic data, pathologic findings and therapeutic implications. Rev Rhum [Engl. Ed.] 1995; 62: CORTET B, FLIPO RM, BLANCKAERT F, DUQUESNOY B, MARCHANDISE X, DEL- CAMBRE B: Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum [Engl Ed] 1997; 64: CORTET B, FLIPO RM, PIGNY P, DUQUESNOY B, BOERSMA A, MARCHANDISE X, DEL- CAMBRE B: Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 1998; 25: SAMBROOK PN, ANSELL BM, FOSTER S, GUMPEL JM, HESP R, REEVE J: Bone turnover in early rheumatoid arthritis. 2. Longitudinal bone density studies. Ann Rheum Dis 1985; 44: SHENSTONE BD, MAHMOUD A, WOODWARD R, ELVINS D, PALMER R, RING EF, BHALLA AK: Longitudinal bone mineral density changes in early rheumatoid arthritis. Br J Rheumatol 1994; 33: GOUGH AKS, LILLEY J, EYRE S, HOLDER RL, EMERY P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994; 344: SAMBROOK PN, COHEN ML, EISMAN JA, POCOCK NA, CHAMPION GD, YEATES MG: Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 1989; 48: REID DM, KENNEDY NS, SMITH MA, TOTHILL P, NUKI G: Bone loss in rheumatoid arthritis and primary generalized osteoarthrosis: Effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements. Br J Rheumatol 1986; 25: EVANS WD, EVANS C: Long-term follow-up of spinal trabecular bone mineral density in women with non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1994; 53: GOUGH A, SAMBROOK P, DEVLIN J et al.: Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: AMAN S, HAKALA M, SILVENNOINEN, MAN- ELIUS J, RISTELI L, RISTELI J: Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: VERHOEVEN AC, BOERS M: Limited bone loss due to corticosteroids; A systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol 1997; 24: KRÖGER H, RISTELI J, RISTELI L, PENTTILÄ I, ALHAVA E: Serum osteocalcin and carboxyterminal propeptide of type I procollagen in rheumatoid arthritis. Ann Rheum Dis 1993; 52: HALL GM, SPECTOR TD, DELMAS PD: Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. Arthritis Rheum 1995; 38: FRANCK H, ITTEL TH, TASCH O, HERBORN G, RAU R: Osteocalcin in patients with rheumatoid arthritis. Effects of anatomical stages, inflammatory activity and therapy. Rheumatol Int 1992; 12: EGGELMEIJER F, PAPAPOULOS SE, WESTEDT ML, VAN PAASSEN HC, DIJKMANS BAC, BREEDVELD FC: Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993; 32: 387, RICO H, REVILLA M, ALVAREZ DE BUERGO M, VILLA LF: Serum osteocalcin and calcitropic hormones in a homogeneous group of patients with rheumatoid arthritis: its implication in the osteopenia of the disease. Clin Exp Rheumatol 1993; 11: GOUGH AKS, PEEL NFA, EASTELL R, HOLDER RL, LILLEY J, EMERY P: Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994; 53: HAKALA M, RISTELI L, MANELIUS J, NIE- MINEN P, RISTELI J: Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 1993; 52: HAKALA M, AMAN S, LUUKKAINEN R, RISTELI L, KAUPPI M, NIEMINEN P, RISTELI J: Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis : COMPSTON JE, VEDI S, CROUCHER PI, GARRAHAN NJ, O SULLIVAN MM: Bone turnover in non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1994; 53: CORTET B, FLIPO RM, PIGNY P, DUQUESNOY B, RACADOT A, BOERSMA A, DELCAMBRE B: How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy. Rev Rhum [Engl Ed] 1997; 64: ARNETT FC, EDWORTHY SM, BLOCH DA, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: RITCHIE DM, BOYLE JA, MCINNES JM, JAS- ANI MK, DALAKOS TG, GRIEVESON P, BUCHANAN VW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: LEE P, JASANI MK, WILLIAM HJ and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Scand J Rheumatol 1973; 2: GUILLEMIN F, BRIANÇON S, POUREL J: Mesure de la capacité fonctionnelle dans la polyarthrite rhumatoïde: Adaptation française du Health Assesssment Questionnaire. Rev Rhum Mal Ostéoartic 1991; 58: CORTET B, HACHULLA E, BARTON I, BON- VOISIN B, ROUX C: Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with in- 689
8 Bone loss in RA / B. Cortet et al. flammatory rheumatic diseases. A randomized study. Rev Rhum [Engl. Ed.] 1999; 66: PRESTON SJ, DIAMOND T, SCOTT A, LAURENT MR: Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993; 52: MAENAUT K, WESTHOVENS R, DEQUEKER J: Methotrexate osteopathy, does it it exist? J Rheumatol 1996; 23: BUCKLEY LM, LEIB ES, CARTULARO KS, VACEK PM, COOPER SM: Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24: EGGELMEIJER F, PAPAPOULOS SE, VAN PAASSEN HC et al.: Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, doubleblind trial. Arthritis Rheum 1996; 39: GARNERO P, SORNAY-RENDU E, CHAPUY MC, DELMAS PD: Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11: MARCUS R, HOLLOWAY L, WELLS B, GREENDALE G, JAMES MK, WASILAUSKAS C, KELAGHAN J: The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the postmenopausal estrogen/progestin intervention (PEPI) trial. J Bone Miner Res 1999; 14:
Does active treatment of rheumatoid arthritis limit disease-associated bone loss?
Rheumatology 2002;41:1047 1051 Does active treatment of rheumatoid arthritis limit disease-associated bone loss? A. L. Dolan, C. Moniz 1, H. Abraha 1 and P. Pitt 2 Department of Rheumatology, Queen Elizabeth
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationBone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover. Original Policy Date
MP 2.04.10 Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationG eneralised osteoporosis is a well known phenomenon
617 EXTENDED REPORT Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis H Forsblad d Elia, A Larsen, E Waltbrand, G Kvist, D Mellström,
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationPage: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover
Last Review Status/Date: December 2014 Page: 1 of 12 Management of Osteoporosis and Diseases Description Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially
More informationRandomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density
Scand J Rheumatol 2007;36:351 358 351 Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density B Tengstrand 1, E Larsson 1, L
More informationE. Toussirot, N. U. Nguyen 1, G. Dumoulin 1, F. Aubin 2, J.-P. Ce doz and D. Wendling
Rheumatology 2005;44:120 125 doi:10.1093/rheumatology/keh421 Advance Access publication 5 October 2004 Relationship between growth hormone IGF-I IGFBP-3 axis and serum leptin levels with bone mass and
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationAre glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?
ORIGINAL ARTICLE Korean J Intern Med 2014;29:509-515 Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? Joo-Hyun
More informationDecreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing s syndrome
European Journal of Endocrinology (1999) 141 126 131 ISSN 0804-4643 CLINICAL STUDY Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing
More informationORIGINAL INVESTIGATION. Vertebral Fracture Risk With Long-term Corticosteroid Therapy
ORIGINAL INVESTIGATION Vertebral Fracture Risk With Long-term Corticosteroid Therapy Prevalence and Relation to Age, Bone Density, and Corticosteroid Use Vasi Naganathan, FRACP; Graeme Jones, FRACP, MD;
More informationI mmunosuppressive pulse treatment with intravenous
940 EXTENDED REPORT Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study G Haugeberg, B Griffiths, K B Sokoll, P Emery... See
More informationResearch Article Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of Type I Collagen in Patients with Ankylosing Spondylitis
BioMed Research International Volume 2015, Article ID 543806, 6 pages http://dx.doi.org/10.1155/2015/543806 Research Article Serum Vitamin D and Pyridinoline Cross-Linked Carboxyterminal Telopeptide of
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationBone Mineral Density in a Cohort of Young Adult Women using Depoprovera and Tenofovir, Kampala, Uganda
Bone Mineral Density in a Cohort of Young Adult Women using Depoprovera and Tenofovir, Kampala, Uganda Flavia Matovu Kiweewa, Noah Kiwanuka, Delia Scholes, Esther Isingel, Mary Glenn Fowler, Clemensia
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationBone Mineral Density Changes in Patients with Recent-Onset Rheumatoid Arthritis
Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Bone Mineral Density
More informationCOLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER
Oxford COLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER UnitedHealthcare Oxford Clinical Policy Policy Number: RADIOLOGY 006.27 T2 Effective Date: November 1, 2018 Instructions for Use Table
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationPage: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover
Last Review Status/Date: March 2017 Page: 1 of 12 Management of Osteoporosis and Diseases Description Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially
More informationSIGNIFICANCE OF ELEVATED INTERLEUKIN-6 LEVEL IN JUVENILE RHEUMATOID ARTHRITIS PATIENTS
SIGNIFICANCE OF ELEVATED INTERLEUKIN-6 LEVEL IN JUVENILE RHEUMATOID ARTHRITIS PATIENTS Essam Tewfik Attwa and S. Al-Beltagy* Rheumatology & Rehabilitation Department, Zagazig University Faculty of Medicine
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationCOLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER
MEDICAL POLICY COLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER Policy Number: 2014T0419J Effective Date: April 1, 2014 Table of Contents BENEFIT CONSIDERATIONS COVERAGE RATIONALE APPLICABLE
More informationCOLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER
COLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER UnitedHealthcare Oxford Clinical Policy Policy Number: RADIOLOGY 006.25 T2 Effective Date: April 1, 2017 Table of Contents Page INSTRUCTIONS
More informationBone mineral density and vertebral compression fracture rates in ankylosing spondylitis
Annals of the Rheumatic Diseases 1994; 53: 117-121 117 Rheumatology, Whipps Cross Hospital, Leytonstone, London, United S Donnelly D V Doyle A Denton I Rolfe Human Metabolism, University of Sheffield Medical
More informationEDUCATION PRACTICE. Osteoporosis in Patients With Inflammatory Bowel Disease. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:152 156 EDUCATION PRACTICE Osteoporosis in Patients With Inflammatory Bowel Disease CHARLES N. BERNSTEIN University of Manitoba IBD Clinical and Research
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 10, 2002 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationFRUIT AND VEGETABLE INTAKE IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA
FRUIT AND VEGETABLE INTAKE IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA Samira Ebrahimof, Anahita Hoshyarrad, Arash Hossein-Nezhad Nahid Zandi, Bagher Larijani, Masoud Kimiagar Abstract INTRODUCTION: Adequate
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationOmnisense: At Least As Good As DXA
Omnisense: At Least As Good As DXA The following document summarizes a series of clinical studies that have been conducted to compare between different qualities of the Sunlight support the claim that
More informationAlendronate sodium in the management of osteoporosis
REVIEW Alendronate sodium in the management of osteoporosis P J J Prinsloo 1 D J Hosking 2 1 Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2 Dept Endocrinology and Diabetes, City Hospital,
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationAuthor's response to reviews
Author's response to reviews Title:The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis Authors: Kristyna Brabnikova
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationProphylactic treatment for osteoporosis: Student EBM Presentation
Prophylactic treatment for osteoporosis: Student EBM Presentation Callum Harris & Ealish Swift University of Oxford October 2015 Example patient JS is a 67 year old lady who needs to start taking long-term
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationUniversity of Medicine and Pharmacy Craiova. Faculty of Medicine. PhD THESIS ABSTRACT
University of Medicine and Pharmacy Craiova Faculty of Medicine PhD THESIS ABSTRACT STUDY OF THE CHANGES IN BONE MASS AND BONE METABOLISM MARKERS IN THYROTOXIC OSTEOPOROSIS. THERAPEUTIC IMPLICATIONS. Scientific
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationBone Mineral Density in Thai Patients with Chronic Hepatitis C, before and after Treatment with Pegylated Interferon/Ribavirin Combination ABSTRACT
Original Article 73 before and after Treatment with Pegylated Interferon/Ribavirin Combination Bunchorntavakul C 1 Chotiyaputta W 1 Sriussadaporn S 2 Tanwandee T 1 ABSTRACT Background: Loss of bone mineral
More informationBone mass in patients with rheumatoid arthritis
826 Annals of the Rheumatic D)iseases 1992; 51: 826-832 Department of Rheumatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijimegen, The Netherlands R F J M Laan P L C M van Riel L B A van
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationG. Poór for the Leflunomide Multinational Study Group and V. Strand 1
Rheumatology 2004;43:744 749 Advance Access publication 16 March 2004 Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind,
More informationPROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS
British Journal of Rheumatology 1995;34:1146-1150 PROGNOSTIC VALUE OF QUANTITATIVE MEASUREMENT OF RHEUMATOID FACTOR IN EARLY RHEUMATOID ARTHRITIS L. PAEVDELA, T. PALOSUO,* M. LEIRISALO-REPO,t T. HELVE
More informationCOLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER
UnitedHealthcare Commercial Medical Policy COLLAGEN CROSSLINKS AND BIOCHEMICAL MARKERS OF BONE TURNOVER Policy Number: 2018T0419N Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...
More informationJ. van Aken* H. van Dongen* S. le Cessie F.C. Breedveld T.W.J. Huizinga. * both authors contributed equally
CHAPTER Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study J. van Aken* H. van
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationA randomised trial of diverentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side evects
Ann Rheum Dis 1999;58:713 718 713 Rheumatology, Hvidovre Hospital, University of Copenhagen, Denmark M Hansen M Stoltenberg Rheumatology and Radiology, Herlev Hospital, University of Copenhagen, Denmark
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationIndex. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.
Rheum Dis Clin N Am 32 (2006) 775 780 Index Note: Page numbers of article titles are in boldface type. A AACE (American Association of Clinical Endocrinologists), bone mineral density recommendations of,
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationLOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
Locally Available Biologic Agents in the Treatment of Psoriatic Arthritis 253 Phil. J. Internal Medicine, 47: 253-259, Nov.-Dec., 2009 LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
More informationdevelopment of the method, and its application
Annals of the Rheumatic Diseases 1994; 53: 685-690 685 Duke of Cornwall Rheumatology Unit, Royal Cornwall Hospital, Truro, Cornwall, United Kingdom A A Deodhar J Brabyn M J Davis A D Woolf Department of
More informationBone mineral density and bone turnover in spinal
Annals ofthe Rheumatc Diseases 1995; 54: 867-871 867 EXTENDED REPORTS Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Northern General Hospital, Sheffield, United Kingdom
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationScintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia Rheumatica
The Open General and Internal Medicine Journal, 29, 3, 53-57 53 Open Access Scintigraphic Findings and Serum Matrix Metalloproteinase 3 and Vascular Endothelial Growth Factor Levels in Patients with Polymyalgia
More informationPredictors of radiological progression and changes in hand bone density in early rheumatoid arthritis
Rheumatology 2003;42:268 275 doi:10.1093/rheumatology/keg077, available online at www.rheumatology.oupjournals.org Predictors of radiological progression and changes in hand bone density in early rheumatoid
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOsteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis
Influence of bone densitometry results on the treatment of osteoporosis Nicole S. Fitt, * Susan L. Mitchell, * Ann Cranney, Karen Gulenchyn, Max Huang, * Peter Tugwell Abstract Background: Measurement
More informationStudy of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease
26 ORIGINAL ARTICLE Study of Bone Mineral Density (BMD) in Patients with Rheumatoid Arthritis and its Corelation with Severity of the Disease Liyakat Ali Gauri 1, Qadir Fatima 2, Sharanbasu Diggi 3, Asim
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationJournal of Hainan Medical University. Wei Li. 1. Introduction. 28 Journal of Hainan Medical University 2016; 22(21): 28-32
28 Journal of Hainan Medical University 2016; 22(21): 28-32 Journal of Hainan Medical University http://www.hnykdxxb.com Dual-energy X-ray absorptiometry assessment of postmenopausal women with vertebral
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationJ A Hughes, B G Conry, S M Male, R Eastell
Thorax 1999;54:223 229 223 Kent & Sussex Hospital, Tunbridge Wells, Kent TN4 8AT, UK J A Hughes B G Conry S M Male Northern General Hospital, SheYeld S5 7AU, UK R Eastell Correspondence to: Dr J A Hughes.
More informationGLUCOCORTICOIDS SUPpress
ORIGINAL INVESTIGATION Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis Results From a Randomized Placebo-Controlled Trial Glenn Haugeberg, MD, PhD; Anders Strand; Tore
More informationDescription of Study Protocol. Data Collection Summary
AND Evidence Analysis Worksheet Citation Kostoglou-athanassiou I, AthanassiouP, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab. 2012; 3(6):181-7. Study
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationSTUDY ON THE EFFECTS OF PHYTOESTROGENS ON BONE RESORPTION IN MENOPAUSE
Analele Universităţii din Oradea, Fascicula Protecţia Mediului Vol. XX, 2013 STUDY ON THE EFFECTS OF PHYTOESTROGENS ON BONE RESORPTION IN MENOPAUSE Ţiţ Delia-Mirela *, Lazăr Liviu **, Bungău Simona*, Iovan
More informationAN APPROACH TO THE PATIENT WITH OSTEOPOROSIS. Malik Mumtaz
Malaysian Journal of Medical Sciences, Vol. 8, No. 1, Januari 2001 (11-19) BRIEF ARTICLE Department of Medicine School of Medical Sciences, Universiti Sains Malaysia 16150 Kubang Kerian, Kelantan, Malaysia
More informationAudit on follow-up of patients with primary Osteoporosis
Abstract Aim: To document the frequency of Dual-energy X- ray absorptiometry (DEXA) scanning and Rheumatology clinic follow-up visits of patients with primary osteoporosis, and compare these with recommended
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationSupplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationDeterminants of Reduced Bone Mineral Density and Increased Bone Turnover after Kidney Transplantation: Cross-sectional Study
398 41(4):396-400,2000 CLINICAL SCIENCES Determinants of Reduced Bone Mineral Density and Increased Bone Turnover after Kidney Transplantation: Cross-sectional Study Vesna Kušec, Ru ica Šmalcelj 1, Selma
More informationrheumatica/giant cell arteritis on presentation and
Annals of the Rheumatic Diseases 1989; 48: 667-671 Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow
More informationTREAT-TO-TARGET IN RHEUMATOID ARTHRITIS
TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS To receive up to 10 CME credits for this activity, complete the evaluation, attestation and post-test answer sheet (minimum passing grade of 70%) and return all
More information